Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 801 - 900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 801 | 25078672 |
US |
52 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 802 | 25078707 |
US |
1 | |
Product storage error, No adverse event, |
||||
| 803 | 25079167 |
US |
7 | 2 |
Product storage error, No adverse event, |
||||
| 804 | 25079938 |
US |
||
No adverse event, Product distribution issue, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 805 | 25080148 |
US |
||
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN, |
||||
| 806 | 25071714 |
US |
31 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 807 | 25071747 |
US |
68 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 808 | 25072081 |
US |
58 | 2 |
Product dose omission issue, Device malfunction, No adverse event, Wrong technique in device usage process, |
||||
OMALIZUMAB, FLUOXETINE HYDROCHLORIDE, |
||||
| 809 | 25072129 |
US |
48 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 810 | 25072137 |
US |
2 | |
Wrong technique in product usage process, No adverse event, Accidental exposure to product, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 811 | 25072139 |
US |
50 | 2 |
Accidental exposure to product, Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, |
||||
| 812 | 25072140 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 813 | 25072141 |
US |
78 | 2 |
Wrong technique in product usage process, Product complaint, No adverse event, |
||||
TOCILIZUMAB, ROSUVASTATIN, LEFLUNOMIDE, ADALIMUMAB, |
||||
| 814 | 25072144 |
US |
48 | 2 |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 815 | 25072480 |
US |
62 | 2 |
Device malfunction, Device defective, No adverse event, Wrong technique in device usage process, Product communication issue, Wrong technique in device usage process, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, VALSARTAN, |
||||
| 816 | 25072684 |
US |
76 | |
Expired product administered, No adverse event, |
||||
| 817 | 25072840 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 818 | 25072969 |
US |
32 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 819 | 25072972 |
US |
||
Product storage error, Product communication issue, Circumstance or information capable of leading to medication error, No adverse event, |
||||
CEPHALEXIN, |
||||
| 820 | 25073009 |
US |
79 | |
Circumstance or information capable of leading to device use error, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, SIMVASTATIN, METHOTREXATE SODIUM, |
||||
| 821 | 25073066 |
US |
53 | 2 |
No adverse event, Product use in unapproved indication, |
||||
DEXLANSOPRAZOLE, |
||||
| 822 | 25073070 |
US |
||
Off label use, Product preparation error, No adverse event, |
||||
ALTEPLASE, |
||||
| 823 | 25073087 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 824 | 25073125 |
US |
77 | |
Wrong technique in product usage process, Drug dose omission by device, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 825 | 25073236 |
US |
||
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 826 | 25073257 |
US |
||
Drug ineffective, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE, |
||||
| 827 | 25073259 |
US |
1 | |
Accidental overdose, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 828 | 25073265 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 829 | 25073315 |
US |
8 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 830 | 25073321 |
US |
1 | |
No adverse event, Product supply issue, Device failure, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 831 | 25073517 |
US |
2 | |
Maternal exposure before pregnancy, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 832 | 25073665 |
US |
||
Overdose, No adverse event, |
||||
RISDIPLAM, |
||||
| 833 | 25073829 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, LISINOPRIL, BACLOFEN, OIL, BIOTIN, HAIR, DULOXETINE HYDROCHLORIDE, DULOXETINE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, GABAPENTIN, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, QUETIAPINE, SERTRALINE, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, SULFASALAZINE, TOPIRAMATE, TOPIRAMATE SPINKLE, |
||||
| 834 | 25073836 |
US |
60 | |
Product packaging quantity issue, Device deposit issue, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 835 | 25073890 |
US |
65 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, OXYGEN, 0XYGEN, |
||||
| 836 | 25073968 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 837 | 25074072 |
US |
36 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 838 | 25074208 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 839 | 25074259 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 840 | 25074260 |
US |
||
Wrong technique in device usage process, No adverse event, |
||||
TIOTROPIUM BROMIDE, |
||||
| 841 | 25074263 |
US |
77 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 842 | 25074400 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 843 | 25074462 |
US |
5 | |
Drug dose omission by device, Wrong technique in product usage process, Product storage error, No adverse event, |
||||
ALBUTEROL SULFATE, LORATADINE, LORATADINE ORAL, |
||||
| 844 | 25074583 |
US |
||
Drug ineffective, No adverse event, |
||||
| 845 | 25074893 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 846 | 25075107 |
US |
61 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 847 | 25075123 |
US |
35 | 1 |
No adverse event, |
||||
NALTREXONE, NICOTINE, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, FEXOFENADINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, |
||||
| 848 | 25075218 |
US |
||
No adverse event, |
||||
RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, |
||||
| 849 | 25075616 |
US |
63 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, |
||||
| 850 | 25075646 |
US |
61 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE, |
||||
| 851 | 25075670 |
US |
59 | |
Device delivery system issue, Drug dose omission by device, Product use in unapproved indication, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 852 | 25075693 |
US |
||
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 853 | 25075771 |
US |
||
Circumstance or information capable of leading to medication error, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, LACTULOSE, |
||||
| 854 | 25075963 |
US |
48 | 2 |
Device leakage, Exposure via skin contact, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 855 | 25075964 |
US |
2 | |
Device defective, Device malfunction, Product dose omission issue, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 856 | 25076066 |
US |
41 | 1 |
Product dose omission issue, Product use issue, No adverse event, Off label use, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
| 857 | 25076681 |
US |
60 | 2 |
Off label use, No adverse event, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 858 | 25076822 |
US |
35 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 859 | 25066067 |
US |
73 | 2 |
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 860 | 25066090 |
US |
||
No adverse event, Product solubility abnormal, Product reconstitution quality issue, |
||||
| 861 | 25066112 |
US |
||
No adverse event, |
||||
SELINEXOR, ACYCLOVIR, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, GABAPENTIN, MORPHINE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE, |
||||
| 862 | 25066167 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, FAMOTIDINE, MONTELUKAST, PREDNISONE, |
||||
| 863 | 25066260 |
US |
||
Product storage error, No adverse event, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 864 | 25066327 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 865 | 25066336 |
US |
||
Intercepted product storage error, No adverse event, |
||||
ALTEPLASE, |
||||
| 866 | 25066394 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 867 | 25066783 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 868 | 25066786 |
US |
79 | |
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 869 | 25066804 |
AU |
||
No adverse event, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 870 | 25066814 |
US |
35 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 871 | 25066848 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 872 | 25066852 |
US |
60 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 873 | 25066871 |
US |
54 | 1 |
Product dose omission issue, Product quality issue, No adverse event, Product communication issue, |
||||
OMALIZUMAB, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, EVOLOCUMAB, FENOFIBRATE, LISINOPRIL, HYDROCHLOROTHIAZIDE, |
||||
| 874 | 25066891 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 875 | 25066899 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 876 | 25066901 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 877 | 25066908 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 878 | 25066913 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 879 | 25066938 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 880 | 25066962 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 881 | 25066975 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 882 | 25066998 |
US |
||
Off label use, No adverse event, |
||||
TENECTEPLASE, |
||||
| 883 | 25067013 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 884 | 25067015 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 885 | 25067022 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 886 | 25067041 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 887 | 25067058 |
US |
96 | |
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 888 | 25067091 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 889 | 25067115 |
US |
50 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 890 | 25067179 |
US |
2 | |
Wrong technique in product usage process, Drug ineffective, Incorrect product administration duration, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 891 | 25067671 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 892 | 25067672 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 893 | 25067704 |
US |
23 | 1 |
Product complaint, Needle issue, Underdose, No adverse event, |
||||
OMALIZUMAB, |
||||
| 894 | 25067798 |
US |
66 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 895 | 25067950 |
GR |
1 | |
No adverse event, |
||||
ALPROSTADIL, |
||||
| 896 | 25068542 |
US |
2 | |
Product complaint, Product complaint, Underdose, No adverse event, |
||||
OMALIZUMAB, |
||||
| 897 | 25068831 |
CN |
||
Device malfunction, No adverse event, |
||||
INSULIN GLARGINE, |
||||
| 898 | 25069366 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
| 899 | 25069419 |
US |
||
No adverse event, |
||||
BIMATOPROST, |
||||
| 900 | 25069474 |
US |
2 | |
Therapeutic product effect variable, No adverse event, |
||||
LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28